NCT03816332 2025-10-09Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersNational Cancer Institute (NCI)Phase 1 Active not recruiting12 enrolled 13 charts